The BioIT World Conference & Expo is going on in Boston, Massachusetts, highlighting companies and breakthroughs working on the data end of life sciences, whether that’s blockchain, artificial intelligence, machine learning, data science, deep learning or others.
The BioIT World Conference & Expo is going on in Boston, Massachusetts, highlighting companies and breakthroughs working on the data end of life sciences, whether that’s blockchain, artificial intelligence, machine learning, data science, deep learning or others.
Here’s a sample of some of the stories coming out of the conference.
Altos and WASAI Offer Accelerated Genome Sequencing Solution
Altos Computing, a subsidiary of Acer, is collaborating with WASAI Technology, which focuses on big data. They are together launching a human genome sequencing program that uses Altos BrainSphere AI computing platform combined with WASAI’s proprietary software. It is built on the Altos R380 F4 platform and is compatible with most industry-leading CPUs, Memory DIMM slots, and high-speed IO.
“We’ve definitely seen an upward trend when it comes to clients requesting fully integrated systems to handle the growing demands of big data analysis,” stated Jackie Lee, president of Altos Computing.
Genomenon Partners with Google for Genomic Data
Genomenon is partnering with Google to make its genomic mutation data available on Google Cloud Platform. Genomenon’s Cited Variants Reference (CVR) data will be available in BigQuery as a public dataset. BigQuery is Google Cloud’s big data and machine learning data warehouse used for genomic applications.
Genomenon’s Mastermind genomic database holds a comprehensive index of genomic literature. The CVR will be designed to assist clinicians and researchers in prioritizing and scaling their interpretation of genomic data.
1CellBiO Presents Custom Targeted Bead Program for Single-Cell Analysis
1CellBiO, a single-cell analysis company, is offering a new program to supply customers with its proprietary inDrophydrogel beads. These are synthesized with custom primers that target transcripts specified by their clients. It allows researchers to focus their sequencing depth on specific genes of interest instead of the full transcriptome.
“We believe the ability to customize and target transcriptional regions of interest will accelerate clinical and pharmaceutical research applications of single-cell RNA-seq,” stated Colin J.H. Brenan, 1CellBio’s chief executive officer.
Qatar Biobank Chooses BC Platforms for Genomic and Phenotypic Data Management
Qatar Biobank, a member of Qatar Foundation (QF) and part of QF Research, Development and Innovation (QF RDI), signed an agreement with BC Platforms, a leader in genomic data management and analytics. BC Platforms will provide a Research Collaboration Management System (RCMS) and Researchers Portal for Qatar Biobank. QF collects data and biological samples from the local population to develop customized medical solutions to diseases and health issues common in the country.
“As the Qatar National Research Strategy strives to improve the health and well-being of Qatar’s population, scientific research collaborations enabled by Qatar Biobank are the key to impacting the future of personalized healthcare in Qatar and the region,” stated Nahla Afifi, director of Qatar Biobank.
Certara Adds 4 Well-Known Global Experts to its Symmcyp PBPK, QSP and QSTS Modeling and Simulation Division
Certara, which focuses on model-informed drug development, regulatory science, real-world evidence and market access services, announced four senior executive appointments to its Simcyp division. Simcyp provides innovative mechanistic modeling technologies that are used to inform drug development.
Rob Aspbury will join as chief operating officer. He was previously vice president of Covance Strategic Solutions, Biosimilars.
Frederic Yves Bois will be the division’s new senior scientific advisor and head of Mechanistic Modeling. Before joining Certara, Bois was research director of the French National Institute for Industrial Environment and Risks (IONERIS).
Will Redfern will take on the role of vice president, Quantitative Systems Toxicology and Safety. He was previously principal scientist for Safety and Mechanistic Pharmacology for AstraZeneca R&D in Cambridge (UK).
Noriko Okudaira will be senior consultant/scientific advisor supporting Certaras clients locally in Japan. She previously acted as director of Daiichi Sankyo’s Clinical Pharmacology Department.
